TLSA Stock Forecast & Price Target

Tiziana Life Sciences is positioned favorably because foralumab has repeatedly shown biologically meaningful reductions in CNS inflammation across SPMS, MSA, and AD, supporting a differentiated, mechanism-based thesis built on Treg induction through intranasal delivery. The company’s near-term setup is attractive: the 48-patient INFORM-MS Phase 2a trial is fully enrolled, topline data are expected in October, and prior evidence includes stability or improvement in all 14 Expanded Access Program patients, with no serious adverse events reported over 37 patient years of exposure. With no approved disease-modifying therapy in MSA, limited options in non-active SPMS, and additional readouts expected in 1H27, the pipeline offers multiple shots on goal and meaningful de-risking if biomarker improvements translate into clinical benefit.

Tiziana Life Sciences is a clinical-stage biotech with no approved products, a limited operating history, and significant execution risk across SPMS, MSA, Alzheimer’s, and ALS programs. Its lead asset, Foralumab, faces steep scientific and regulatory hurdles because neurodegeneration biology is complex, later-stage patients are harder to treat, and the FDA may ultimately require larger, well-controlled datasets and possibly two trials for full approval, which could increase trial costs and delay commercialization. The company has incurred significant operating losses since inception and will likely need substantial additional capital, while competitive pressure is intensifying from NLRP3 inhibitors and established anti-inflammatory programs, making dilution and pipeline risk key concerns.